October 02, 2025

RP1 Oncolytic Therapy Provides New Hope for Patients Whose Melanoma Resists Conventional Immunotherapy

About half of all patients with advanced melanoma face a poor prognosis because their cancer doesn’t respond to immunotherapy — but results of a recent clinical trial show that an unusual treatment strategy could change that.

Roswell Park Comprehensive Cancer Center

September 29, 2025

Sunburns Linked to Squamous Cell Carcinoma Risk

Childhood severe sunburns carry 3-fold higher cancer risk than adult exposure

Conexiant

September 25, 2025

Utah Study Finds Fewer Melanoma Cases With Tattoos

Tattooed patients show varying melanoma risks by session number.

Conexiant

January 01, 0001

The Hodi Paper: A Researcher’s View

Discover how innovative trial designs impact treatment paradigms for metastatic melanoma patients through ipilimumab's study findings.

JADPRO

May 27, 2021

Study Finds Adjuvant Immunotherapy of Benefit to Patients With Stage IIB/C Melanoma

A significant survival advantage accrued to patients with stage IIB and IIC cutaneous melanoma who received adjuvant immunotherapy, a large retrospective cohort study reported at the Society of Surgic...

The ASCO Post

April 30, 2024

Study Explores Impact of Cannabis Extract on Melanoma Cells

The cannabis extract cannabinoid PHEC-66 may effectively treat melanoma.

Conexiant

April 30, 2024

Model for Predicting Survival Following SLNB in Melanoma

Researchers have developed a model for the prediction of recurrence-free and melanoma-specific survival after sentinel lymph node biopsy (SLNB) in patients with melanoma.

Conexiant

April 29, 2024

Adjuvant mRNA-Based Personalized Therapy Plus Immunotherapy in High-Risk Resected Melanoma

The addition of a novel mRNA-based individualized neoantigen therapy to pembrolizumab may improve recurrence-free survival in patients with completely resected high-risk cutaneous melanoma.

Conexiant

August 21, 2023

Ipilimumab Plus Nivolumab May Improve Outcomes in Patients With Refractory Metastatic Melanoma, Study Suggests

Researchers have discovered that ipilimumab in combination with nivolumab may be an effective second-line therapy in patients with PD-1 blockade–refractory metastatic melanoma, according to a recent s...

The ASCO Post